New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier

Nairobi/Khartoum – 12 September 2018

Trial to take place in Sudan, which has the world’s highest rates of this highly stigmatizing disease
A clinical trial to find a better treatment for severe or chronic cases of post kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan. The objective of this clinical trial, which is being conducted by the DNDand the Institute for Endemic Diseases at the University of Khartoum, is to shorten the length of hospitalization for PKDL, and deliver a treatment that is safer to use and easier to administer.

Keystone Conference 2018

21st Century Drug Discovery and Development for Global Health

17-20 October 2018
Berlin, Germany
Nathalie Strub-Wourgaft, NTD Director – presentation on the new therapies for sleeping sickness
Charles Mowbray, Discovery Director – presentation on new orally active treatments for leishmaniasis

DNDi announces new Director of Neglected Tropical Diseases

Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme

DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.

National Regulatory Conference (NRC) 2018

2-4 October 2018 
Selangor, Malaysia
Marion Laumonier, Head of Regulatory Affairs – presentation on registration pathways and forum discussion on collaborative efforts between regulators and stakeholders

MedTrop 2018

Congress of the Brazilian Society of Tropical Medicine

2-5 September 2018 
Recife, Brazil
Posters on advances and challenges for Chagas disease and an access project in Colombia
DNDi participating in several round tables on Chagas disease and cutaneous leishmaniasis and the satellite forum FSBEIN

Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa

Addis Ababa – 13 April 2018
Study launched as part of new Afri-KA-DIA Consortium will also assess diagnostic tools
A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis (VL) has begun in eastern Africa, within the new Afri-KA-DIA consortium with funding from The European & Developing Countries Clinical Trials Partnership (EDCTP). The large-scale Phase III clinical trial seeks to assess the efficacy and safety of a combination of miltefosine and paromomycin in treating VL in eastern Africa.

Takeda Pharmaceutical and DNDi collaborate to progress a potential new drug for visceral leishmaniasis through the R&D pipeline

Osaka, Japan and Geneva, Switzerland – 5 April 2018
Efforts funded by the Global Health Innovative Technology Fund for pre-clinical and phase I clinical studies
Takeda Pharmaceutical Co., Ltd. and DNDtoday announced that they have signed an agreement to collaborate in conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the aminopyrazole compound class, aimed at developing an innovative drug for the treatment of visceral leishmaniasis (VL).
[Japanese]